Key facts
- Notable investors include Shenzhen Yifeng Investment Management Enterprise, Med-Fine Capital, Zeyue Venture Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Castalysis Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Castalysis Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Castalysis Bioscience
Developer of genetic drugs designed to cure genetic diseases. The company is committed to clinically transforming efficient ultra-small gene editors into genetic drugs with ultra-small and efficient gene editor alphaCas, a metagenomic-based gene editor mining platform, providing advanced gene editing and medical solutions for genetic diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2023
- Ownership
- Privately Held (backing)
Castalysis Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Castalysis Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Castalysis Bioscience in its N-PORT filings yet. We sweep new filings monthly.